eli lilly retatrutide clinical trials Retatrutide, Lilly's next generation of weight loss injections, showed dramatic results in trials, with patients losing an average of up to 71.2 pounds, or 28.7% of their body weight. Eli Retatrutide clinical trial done! Now

Eli Lilly, the drugs aboveboard manufacturer, is currently completing Phase III trials

Many people who think retatrutide ruined their exercise capacity are actually just dehydrated

Tracking switching between medications: Understand why and when patients switch between different GLP-1 therapies

You might notice excessively large thighs and cylindrical legs with a sharp cut-off at the ankles, frequently referred to as the cuff-sign. The hands and feet usually remain completely unaffected, though some patients develop painful fatty nodules around their ankles

Scrambled eggs are particularly well-tolerated when appetite is low